Biblio
“a phase III trial of carboplatin and paclitaxel plus placebo versus carboplatin and paclitaxel plus concurrent bevacizumab followed by placebo, versus carboplatin and paclitaxel plus concurrent and extended bevacizumab, in women with newly diagnosied, pre”, N Engl J Med, vol. 365, p. 2483, 2011.
, “Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study”, J Clin Oncol, vol. 23, pp. 4626-33, 2005.
, “No socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials”, Br J Cancer, vol. 111, pp. 589-97, 2014.
, “Advancing clinical research globally: Cervical cancer research network from Mexico.”, Gynecol Oncol Rep, vol. 25, pp. 90-93, 2018.
, “Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience”, Ann Oncol, vol. 21, pp. 2377-81, 2010.
“CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.”, Br J Cancer, vol. 106, no. 4, p. 637, 2012.
, “Advanced epithelial ovarian cancer: 1993 consensus statements.”, Ann Oncol, vol. 4 Suppl 4, pp. 83-8, 1993.
, “Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S67-72, 2014.
, “Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study”, Clin Cancer Res, vol. 19, pp. 5485-93, 2013.
, “Fertility preservation: A key survivorship issue for young women with cancer ”, Frontiers in Oncology , vol. 6, no. 102, 2016.
, “Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010.”, Gynecol Oncol, vol. 121, no. 2, pp. 407-15, 2011.
, “Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial”, Br J Cancer, vol. 107, pp. 785-92, 2012.
, “Intraperitoneal cisplatin and paclitaxel in ovarian cancer”, N Engl J Med, vol. 354, pp. 34-43, 2006.
, “Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.”, Lancet, vol. 373, no. 9658, pp. 125-36, 2009.
, “Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis.”, Lancet, vol. 373, no. 9658, pp. 137-46, 2009.
, “Pegylated liposomal doxorubicin-carboplatin vs paclitaxel-carboplatin in relapsing sensitive ovarian cancer: a 500-patient interim safety analysis of the CALYPSO GCIG intergroup phase III study. ”, Proc.Am.Soc.Clin.Oncol. , vol. 26, no. 15S Part I, 2008.
, “The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 746-9, 2011.
, “Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions.”, Cells, vol. 8, no. 3, 2019.
, “A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG.”, Ann Oncol, vol. 24, no. 3, p. 687, 2013.
, “A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.”, Gynecol Oncol, vol. 163, no. 1, pp. 72-78, 2021.
, “Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study”, J Clin Oncol, vol. 24, pp. 587-92, 2006.
, “Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial”, Ann Oncol, vol. 19, pp. 898-902, 2008.
, “Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study”, Gynecol Oncol, vol. 102, pp. 432-9, 2006.
, “[Epithelial ovarian cancer (advanced stage): consensus conference (1998)].”, Gynecol Obstet Fertil, vol. 28, no. 7-8, pp. 576-83, 2000.
, “Advanced epithelial ovarian cancer: 1998 consensus statements.”, Ann Oncol, vol. 10 Suppl 1, pp. 87-92, 1999.
,